5Teo SK.Properties of thalidomide and its analogues:implications for anticancer therapy[J ] . The AAPS Journal, 2005,7(1): 14.
6Corral L,Haslett P,Muller G,et al .Differential cytokine modulation and T cell activation by 2 distinct classes of thalidomide analogues that are potent inhibition of TNF [alpha][J].J Immunol ,1999,163(1) :380.
7Marriott JB, Clarke IA, Dredge K, et al .Thalidomide and its analogs have distinct and opposing effects on TNF [alpha] and TNFR2 during co stimulation ofboth CD4+ and CD8+ Cells[J] .Clin Exp Immunol,2002,130(1) : 75.
8D' Amato R, Loughnan M, Flynn E, et al. Thalidomide is an inhibitor of angiogenesis[J ] .Proc Natl Acad Sci USA, 1994,91(9) : 4 082.
9Bauernhofer T, Kuss I, Henderson B, et al. Preferential apoptosis of CD56dim natural killer cell subset in patients with cancer[J ] .Eur J Immunol,2003,33(1) :119.
10Hideshima T, Chauhan D, Shima Y, et al .Thalidomide and its analog overcome drug resistance of human multiple myeloma cells to conventional therapy[J] .Blood,2000,96(9) :2 943.
二级参考文献39
1Gardner-Medwin JMM, Smith NJ, Powell RJ. Clinical experience with thalidomide in the management of severe oral and genital ulceration in conditions such as Behcet's disease: use of neurophysiological studies to detect thalidomide neuropathy. Ann Rheum Dis
2Coleman M, Leonard JP, Nahum K,et al. Non-myelosuppressive therapy with blt-d [Bianxin(r), low dose thalidomide and dexamethasone] is highly active in Waldenstrom's macroglobulinemia and myeloma. Blood, 2000, 96: 167.
3Van den Bosch F, Kruithof E, Baeten D, et al. Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study. Ann Rheum Dis, 2000, 59:428-433.
4Hashimoto Y. Novel biological response modifiers derived from thalidomide. Curr Med Chem, 1998, 5: 163-178.
5Barba RJ, Franco GF. Fixed lupus erythematosus (its treatment with thalidomide). Med Cutan Ibero Lat Am, 1977, 5: 279-285.
6Stevens R J, Andujar C, Edwards CJ, et al. Thalidomide in the treatment of the cutaneous manifestations of lupus erythematosus:experience in sixteen consecutive patients. Br J Rheumatol, 1997,36: 353-359.
7Alfadley A, Al-Rayes H, Hussein W, et al. Thalidomide for treatment of severe generalized discoid lupus lesions in two patients with systemic lupus erythematosus. J Am Acad Dermatol, 2003,48(Suppl 5): 89-91.
8Knop J, Bonsmann G, Happle R, et al. Thalidomide in the treat ment of sixty cases of chronic discoid lupus erythematosus. Br J Dermatol, 1983, 108: 461-466.
9Mascaro JM, Lecha M, Torras H. Thalidomide in the treatment of recurrent, necrotic,and giant mucocutaneous aphthae and aphthosis. Arch Dermatol, 1979, 115: 636-637.
10Saylan T, Saltik I. Thalidomide in the treatment of Behcet's syndrome. Arch Dermatol, 1982, 118: 536.
